High-level co-expression of complement regulators on vascular endothelium in transgenic mice: CD55 and CD59 provide greater protection from human complement-mediated injury than CD59 alone

Xenotransplantation

Volumn 5, Issue 3, 1998, Pages 184-190

  Cowan, Peter J ^a   Shinkel, Trixie A ^a   Aminian, Atousa ^a   Romanella, Margarita ^a   Wigley, Peter L ^b   Lonie, Andrew J ^b   Nottle, Mark B ^b   Pearse, Martin J ^a   D'Apice, Anthony J F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b PO Box 259 Rundle Mall   (Australia)

Author keywords

CD55; CD59; Complement; Endothelium; Xenotransplantation

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR;

ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GRAFT REJECTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

EID: 0031667615     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.1998.tb00026.x     Document Type: Article

References (25)

1. DALMASSO AP. Role of complement in xenograft rejection. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation. Berlin: Springer-Verlag, 1997.
2. FODOR WL, WILLIAMS BL, MATIS LA, MAORI JA, ROLLINS, SA, KNIGHT JW, VELANDER W, SQUINTO SP. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91:11153.
3. BYRNE G, MCCURRY KR, MARTIN MJ, MCCLELLAN SM, PLATT JL, LOGAN JS. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63:149.
4. COZZI E, WHITE DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1:964.
5. VAN DENDEREN BJW, PEARSE MJ, KATERELOS M, NOTTLE MB, DU ZT, Aminian A, ADAM WR, SHENOYSCARIA A, LUBLIN DM, SHINKEL TA, D'APICE AJF. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 1996; 61:582.
6. MORA M, MULDER LCF, LAZZERI M, BOSCHI M, CICCOPIEDI E, MELLI CM, BRUZZONE P, ALFANI D, CORTESINI R, ROSSINI M. Protection from complement-mediated injury in livers and kidneys of transgenic mice expressing human complement regulators. Xenotransplantation 1996; 3:63.
7. YANNOUTSOS N, IJZERMANS JN, HARKES C, BONTHUIS F, ZHOU CY, WHITE D, MARQUET RL, GROSVELD F. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection. Genes Cells 1996; 1:409.
8. THORLEY BR, MILLAND J, CHRISTIANSEN D, LANTERI MB, MCINNES B, MOELLER I, RIVAILLER P, HORVAT B, RABOURD-INCOMBE C, GERLIER D, MCKENZIE IFC, LOVELAND BE. Transgenic expression of a CD46 (membrane cofactor protein) minigene: Studies of xenotransplantation and measles virus infection. Eur J Immunol 1997; 27:726.
9. KROSHUS TJ, BOLMAN RM, DALMASSO AP, ROLLINS SA, GUILMETTE ER, WILLIAMS BL, SQUINTO SP, FODOR WL. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation. 1996; 61:1513.
10. WHITE DJG, LANGFORD GA, COZZI E, YOUNG VJ. Protective effects of human DAF in transgenic pigs. Xeno 1995; 3:48.
11. COWAN PJ, SOMERVILLE CA, SHINKEL TA, KATERELOS M, AMINIAN A, ROMANELLA M, TANGE MJ, PEARSE MJ, D'APICE AJF. High-level endothelial expression of human CD59 prolongs heart function in an ex vivo model of xenograft rejection. Transplantation 1998; 65:826.
12. COWAN PJ, SHINKEL TA, WITORT EJ, BARLOW H, PEARSE MJ, D'APICE AJF. Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation 1996; 62:155.
13. COYNE KE, HALL SE, THOMPSON ES, ARCE MA, KINOSHITA T, FUJITA T, ANSTEE DJ, ROSSE W, LUBLIN DM. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 1992; 149:2906.
14. HARRISON RA, LACHMANN PJ. Complement technology. In: Weir D, Herzenberg L, Blackwell C, eds. Handbook of Experiment Immunology Part I, Immunochemistry. Blackwell Scientific Publications, 1986.
15. SERVAIS G, WALMAGH J, DUCHATEAU J. Simple quantitative haemolytic microassay for determination of complement alternative pathway activation (AP50). J Immunol Methods 1991; 140:93.
16. TANGE MJ, TEARLE RG, AMINIAN A, ROMANELLA M, ADAM WR, PEARSE MJ, D'APICE AJF. Demonstration of the functional importance of the Gal epitope in an ex vivo model of xenotransplantation. Xenotransplantation 1997; 4:20.
17. MURPHY BF, D'APICE AJF. Identification of the components of glomerular immune deposits using monoclonal antibodies. Pathology 1988; 20:130.
18. DALMASSO AP, VERCELLOTTI GM, PLATT JL, BACH FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor-potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52:530.
19. VAN DENDEREN BJW, PEARSE MJ, D'APICE AJF. The prospects for renal xenotransplantation. Nephrology 1996; 2:217.
20. COZZI E, YANNOUTSOS N, LANGFORD GA, PINO-CHAVEZ G, WALLWORK J, WHITE DJG. Effect of transgenic expression of human decay accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation. Berlin: Springer-Verlag, 1997.
21. SQUINTO SP, FODOR WL. Engineering of xenografts to provide organs for human transplantation. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation. Berlin: Springer-Verlag, 1997.
22. VAN DENDEREN BJW, SALVARIS E, ROMANELLA M, AMINIAN A, KATERELOS M, TANGE MJ, PEARSE MJ, D'APICE AJF. Combination of decay-accelerating factor expression and α1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury. Transplantation 1997; 64:882.
23. PLATT JL, LOGAN JS. Use of transgenic animals as xenotransplant donors. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation. Berlin: Springer-Verlag, 1997.
24. MCCURRY KR, KOOYMAN DL, DIAMOND LE, BYRNE GW, LOGAN JS, PLATT JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation. 1995; 59:1177.
25. COWAN PJ, CHEN C-G, SHINKEL TA, FISICARO N, SALVARIS E, AMINIAN A, ROMANELLA M, PEARSE MJ, D'APICE AJF. Knock out of α1,3-galactosyltransferase or expression of α1,2-fucosyltransferase further protects CD55- and CD59-expressing mouse hearts in an ex vivo model of xenograft rejection. Transplantation (in press).